Latest news ...

Some of our recent news articles.

 
17
June
2019
17th June 2019
 

Pfizer to Acquire Array BioPharma

NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Array BioPharma Inc. (NASDAQ: ARRY) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. Pfizer has agreed to acquire Array for $48 per share in cash, for a total enterprise value of approximately $11.4 billion. The Boards of Directors of both companies have approved the merger.

 
Read the full story »
 
 
01
May
2019
01st May 2019
 

Pfizer reports first-quarter profit that beats estimates

Strong vaccine and cancer drug sales help Merck top earnings expectations and send its shares higher

 
Read the full story »
 
 
13
July
2018
13th July 2018
 

Pfizer set to split company into three units

Pfizer said today it would reorganise into three units, separating its consumer healthcare business that the US drugmaker has been trying to sell since last year.
 
Read the full story »
 
 
04
May
2018
04th May 2018
 

Newer drugs help Pfizer beat profit forecast

Company still expects to make a decision on its consumer health unit during the year
 
Read the full story »
 
 
07
February
2018
07th February 2018
 

Pfizer earnings forecast tops estimates

Pharma group expects to pay $15 billion over eight years to US treasury to repatriate cash
 
Read the full story »
 
 
05
January
2018
05th January 2018
 

Cost of Viagra soars in US as drug hikes come into effect

Pfizer raises average wholesale price of 148 drugs by 6-13.5 per cent
 
Read the full story »
 
 
02
August
2017
02nd August 2017
 

Pfizer M&A on hold pending clarity on US tax reform

Sales slip for third quarter in a row as leading drug group misses analyst projections
 
Read the full story »
 
 
14
June
2017
14th June 2017
 

Pfizer US drug prices jump as Trump prepares for clampdown

Pharma giant increase US price of nearly 100 medicines by average of 20 per cent this year
 
Read the full story »
 
 
14
June
2017
14th June 2017
 

Washington turmoil is proving a bitter pill for Pfizer

Pharma giant facing into expiry of key patents and investors are becoming itchy
 
Read the full story »
 
 
10
May
2017
10th May 2017
 

Pfizer, awaiting a final NICE verdict, doles out free Ibrance in the U.K.

Pfizer is waiting on England’s cost watchdogs to come to a reimbursement conclusion on breast cancer-fighter Ibrance—but it's ending the wait for patients.
 
Read the full story »
 
 
08
May
2017
08th May 2017
 

Pfizer revenue misses estimates as top drugs disappoint

Analysts questioning drug-making giant’s growth potential outside M&A
 
Read the full story »
 
 
30
March
2017
30th March 2017
 

Second time's the charm? Pfizer tries again with OTC Viagra in the U.K.

Pfizer is looking to reclassify Viagra (sildenafil) as a pharmacy medicine in the U.K., almost a decade after its first OTC request.
 
Read the full story »
 
 
07
February
2017
07th February 2017
 

Pfizer set to lose ‘billions of dollars’ as drug patents expire

Pharma giant reports worse-than-expected fourth-quarter results on weak Viagra sales
 
Read the full story »
 
 
01
November
2016
01st November 2016
 

Pfizer pulls plug on cholesterol-lowering drug

Analyst warns decision on bococizumab narrows ‘already thin’ pipeline
 
Read the full story »
 
 
25
August
2016
25th August 2016
 

Pfizer confirms plan to buy Medivation in $14 bln deal

Sanofi, Merck, Celgene and Gilead Sciences also believed to have been interested in firm
 
Read the full story »
 
 
03
August
2016
03rd August 2016
 

Pfizer earnings beat estimates on sales of generics

Largest US drugmaker gives no hint whether it will split but expects decision by year end
 
Read the full story »
 
 
29
June
2016
29th June 2016
 

Pfizer's First Asian Biotech Center Will Be in China

The goal is faster product approvals.
 
Read the full story »
 
 
18
May
2016
18th May 2016
 

Pfizer slots Anacor into deal roster with $4.5B buyout

Pfizer had planned on a seven-course meal with its Allergan buy. But now that the $160 billion buyout is kaput, Pfizer has inked a bite-sized deal worth $4.5 billion for Anacor Pharmaceuticals.

It’s part of Pfizer’s Plan B in the wake of its Allergan deal collapse. CEO Ian Read has said the company will be shopping for deals to beef up the “innovative” side of its business, in preparation for a potential breakup. Investors and analysts have been salivating after that prospect since Read first pitched the idea back in 2013, and Read recently said Pfizer would now decide by year’s end on whether to go forward with a split.
 
Read the full story »
 
 
09
May
2016
09th May 2016
 

Return to growth: Pfizer thanks Hospira and looks to biosimilars

Pfizer has attributed Hospira’s sterile injectables and biosimilar assets to its return to growth, offsetting 17 quarters of declining sales.
 
Read the full story »
 
 
05
May
2016
05th May 2016
 

Pfizer revenue beats expectations on Hospira acquisition

Company had also planned $160bn merger with Allergan but new US rules ended deal
 
Read the full story »
 
 
03
May
2016
03rd May 2016
 

Smiths Group eyes up Pfizer's medical devices in $2bn deal

Engineering conglomerate Smiths Group is looking to beef up its largest division, and is mulling buying the medical devices operations of pharmaceutical giant Pfizer.
 
Read the full story »
 
 
06
April
2016
06th April 2016
 

Pfizer Confirms Termination of Proposed $160 Billion Allergan Merger

Pfizer Inc. and Allergan Plc agreed to end their $160 billion merger, terminating the largest-ever health-care acquisition as officials in Washington crack down on corporate inversions.
 
Read the full story »
 
 
19
February
2016
19th February 2016
 

First-in-class Therapy Now Approved for Use in a Broader Range of Women

Pfizer Receives Expanded FDA Approval For IBRANCE (Palbociclib) In HR+, HER2- Metastatic Breast Cancer

New Indication Supported by Results of Phase 3 PALOMA-3 Trial of IBRANCE in Combination with Fulvestrant
 
Read the full story »
 
 
03
February
2016
03rd February 2016
 

Pfizer misses analysts’ estimates with results

US drugmaker says it is on course with Allergan deal which will see it shift its HQ to Dublin
 
Read the full story »
 
 
18
January
2016
18th January 2016
 

Pfizer and Allergan to mull splitting up again in 2018 say CEOs

The Pfizer-Allergan $160bn merger will create the world’s largest pharma company but potentially not for long, as the two CEOs discuss breaking the entity up in 2018.
 
Read the full story »
 
 
14
January
2016
14th January 2016
 

Pfizer CEO: Allergan deal is 'a lot more about growth' than job cuts

Anyone who's examined Pfizer's ($PFE) job-chopping track record knows the company has a tendency to wield the ax in the wake of a megamerger. Just look at its 2009 Wyeth buy, which spurred an initial announcement of 20,000 job cuts--and many thousands more since.
 
Read the full story »
 
 
24
November
2015
24th November 2015
 

Pfizer takes over Allergan in $160bn deal Deal makes Ireland home to the largest pharmaceutical company in the world

Drug giant Pfizer has announced a $160 billion (€150.5bn) takeover of Dublin-headquartered Allergan in a deal that will make Ireland home to the world’s largest pharmaceutical company.

The all-share transaction will see Pfizer issue 11.3 shares in the enlarged company for each share held by Allergan investors. That values each Allergan share at $363.63.
 
Read the full story »
 
 
24
September
2015
24th September 2015
 

FDA votes 21-3 in favour of Remicade biosimilar; Pfizer preps for 2016 launch

A US FDA advisory committee has voted overwhelmingly in favour of licensing Celltrion and Pfizer’s version of J&J’s Remicade, paving the way for the first US monoclonal antibody biosimilar.
 
Read the full story »
 
 
28
April
2015
28th April 2015
 

Pfizer cuts 2015 forecast as strong dollar hits sales

US pharmaceutical giant Pfizer today reported a slight rise in first-quarter profit but lowered its full-year forecast, citing a hit to sales from the stronger dollar.

Pfizer said that recent changes in foreign exchange rates, mainly the dollar's gains against the weakening euro, would impact foreign sales.

It cut its 2015 full-year sales estimate to $44-$46 billion, from $44.5-$46.5 billion.
 
Read the full story »
 
 
 
 
 
 
 
 
 

About Us

SURIMS is the new name for Actex Pharma Services which was a consultancy established in 2003, supporting companies in the identification, qualification and management of quality vendors and suppliers in ingredients and formulations.

The Pharmaceutical Services Directory supports the identification and on-boarding of quality suppliers and also incorporates software features that manage relationships between suppliers and their customers. These include the building and deployment of questionnaires and assessments, electronic signatures and sign-offs and project management between vendor/partner and customer.

Access to the features and software is available on a 'pay as you go' basis, or a customised version can be licensed for your company for its own supplier on-boarding and supplier management activities. Further information on our software services please contact Tel: +353 87 294 0436 or email info@pharmaservicesdirectory.com

 
 
 

Get in Touch

The Pharmaceutical Services Directory
info@pharmaservicesdirectory.com.

 
 

© 2019 Actex Pharma Services | All Rights Reserved.